StockStory.org on MSN
Patient monitoring stocks Q3 earnings: iRhythm (NASDAQ:IRTC) best of the bunch
Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including ...
Remote monitoring is increasing as new reimbursement paths open up. But even the best programs are no guarantee of success.
The promise of remote patient monitoring is showing itself in more and more telemedicine use cases, with huge potential for day-to-day wellness, management of chronic conditions and the promotion of ...
Experts emphasize that remote patient monitoring (RPM) is most effective when supported by structured care teams and workflows, with artificial intelligence–enabled tools helping to interpret data and ...
Healthcare organizations across the country are launching RPM programs aimed at monitoring specific patient populations outside the hospital. As healthcare organizations look to improve care ...
The Louisville-based health system is working with Cadence to establish the platform in 18 community hospitals in 12 states, with plans to expand the service to all of its 79 hospitals in 25 states.
StockStory.org on MSN
Reflecting on patient monitoring stocks’ Q3 earnings: ResMed (NYSE:RMD)
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...
Growth of remote patient monitoring during the pandemic was driven by a small fraction of primary care physicians using untargeted methods for patient selection, a new study revealed. The study, ...
For patients with rheumatoid arthritis, going to the doctor to discuss any ongoing symptoms or problems can be a hardship, especially if rheumatologists are scarce in their area. A mobile app under ...
Robin Farmanfarmaian is a Silicon Valley-based entrepreneur working in technology and artificial intelligence. She has been involved with more than 20 early-stage biotech and healthcare startups, ...
A recent article from Mayo Clinic President and CEO Gianrico Farrugia, M.D., offers a compelling glimpse of what that future ...
The DETECT study is the first randomised controlled trial comparing Minder System implants to standard care monitoring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results